Tag: FDA
Coronacrisis and Leviathan

In his magisterial Crisis and Leviathan, Robert Higgs shows that the growth of government in the twentieth century can largely be explained by patterns of crisis and response. These crises can be real (World Wars I and II, the Great Depression, stagflation) or imagined (inequality, the various isms). In either case new government programs, agencies, and policies...
Read More »

Favor Local Action to Combat the Coronavirus

Three months ago, the novel coronavirus first appeared in Wuhan, China. Now, it is considered a global pandemic. As of March 18th, the virus has infected over 169,000 individuals, resulting in 8,732 deaths—and counting. The United States as of this writing has approximately 7,769 confirmed cases of the coronavirus and at least 125 related...
Read More »

FDA Acknowledges Coronavirus Is Causing More Drug Shortages

The first outbreak of the coronavirus occurred in China nearly two months ago. The disease quickly spread through the country. As of March 5th, the coronavirus is responsible for over 80,000 confirmed cases and nearly 3,400 deaths across China. Globally over 98,000 people are infected, resulting in nearly 4,000 deaths. At this time, the...
Read More »

FDA’s Approval of Generic Daraprim Offers Lessons on Drugs Prices

In 2015, Turning Pharmaceuticals CEO Martin Shkreli increased the price of the drug Daraprim nearly 5,000 percent from $13.50 to $750 per pill. The price hike generated widespread outrage, earning Shkreli the moniker “Pharma Boy” and the designation, “pharmaceutical greed villain.” Daraprim became “the poster child for the issue of high drug prices.”

What Will the Coronavirus Reveal About Our Healthcare System?

Scientists, doctors, and citizens everywhere are debating how concerned we should be about the outbreak of Coronavirus, also known as COVID-19. With alarming headlines grabbing our attention, the World Health Organization has increased its assessment of the risk of spread and impact to “very high.” Catalyst Fellow Conor Norris has taken a look at...
Read More »

Who Should Regulate Tobacco Products? Less Is More!

Over the past year, the Food and Drug Administration undertook a “historic crackdown” of the e-cigarette industry. Recent bans on selected e-cigarette flavors are certainly a step in this direction. With promises for “aggressive action” by FDA Commissioner Stephen Hahn, more heavy-handed regulations are likely to follow. The FDA certainly has increased its regulatory...
Read More »

FDA Expands Ecstasy Access to Veterans with PTSD

In 2006, Johnathan Lubecky was deployed to Iraq. While fighting for his country, Johnathan faced constant enemy strikes, one of which resulted in a traumatic brain injury. Exposures to the horrors of war resulted in Johnathan developing post-traumatic stress disorder (PTSD).

Politicians Still Misunderstand High Insulin Prices

In 2015, the Centers for Disease Control ranked diabetes seventh among the leading causes of death in the United States. If current trends continue, skyrocketing death rates and other serious consequences of poorly managed diabetes will continue. Managing diabetes is challenging, often requiring strict dieting, regular exercise, and taking a variety of medications. For...
Read More »

Are More Vaping Bans Coming Soon? Let’s Hope Not!

Over the past year, the Food and Drug Administration has seemed determined to “wipe out the entire vaping industry.” As former FDA Commissioner Scott Gottlieb, who spearheaded much of the current anti-vaping movement,” notes: “the FDA is so concerned about the dangerous effects of e-cigarettes on American youth that the products may have to...
Read More »

Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s?

We’re only a few weeks into the new year, and the Food and Drug Administration will soon make a decision that will affect pharmaceutical regulation for decades. Last year, after failing an FDA-required futility test, Biogen abandoned its efforts to develop an Alzheimer’s treatment named aducanumab. However, after conducting an analysis using an expanded...
Read More »

  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org